Rapamycin in combination with other compound or inhibitors had enhanced efficacy against prostate cancer [37] or led to decreased cell proliferation [38], and Giovanni Luca Gravina work also suggested that PI3K/Akt/mTOR inhibitors can be used in hormone-insensitive prostate cancer models [39]. The gene discussed is AKT1; the disease is prostate cancer.